factor ix

DRUG3 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), Novo Nordisk A/S, Tulane University

Conditions

Blood Coagulation DisordersCongenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With InhibitorsHematologic DiseasesHemophilia AHemorrhagic Disorders

Early Phase 1

Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

CompletedNCT05281718

Tulane UniversityHemophilia A

Start: 2022-08-01End: 2024-07-14Updated: 2025-01-20

Phase 3

Cooperative Study of Factor VIII Inhibitors

CompletedNCT00000582

National Heart, Lung, and Blood Institute (NHLBI)Blood Coagulation Disorders, Hematologic Diseases, Hemophilia A +1

Start: 1978-07-31End: 1979-07-31Updated: 2012-04-27

Phase 4

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

CompletedNCT01561391

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors

Start: 1998-04-30End: 2004-05-31Updated: 2023-12-29